Lumida
/HRTX
⌘K
Heron Therapeutics Inc

Heron Therapeutics Inc

HRTX
$0.47USD↓-1.11%-0.01 today

MARKET CAP

89.1M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$0 – $0

52W RANGE

$0
$2

AI Summary

Stalk
Sell NowMedium

HRTX remains in a Stage 4 decline with a clear sequence of lower highs and lower lows. Price trades below the 9, 21, and 50 EMAs, which continue to slope down and act as resistance. Although a Post-Capitulation pattern indicates selling exhaustion at the recent low, the absence of any repair above intermediate EMAs confirms medium-term bearish control. The tradable side is bearish, and execution should involve selling now into failed retests of the short-term EMAs. Key risks include a decisive reclaim of the 9/21 EMAs and a sustained break above the 50 SMA that could invalidate the downtrend.

  • ↑Q1 net revenue $34.7M, up 32% YoY with March sales over $15M
  • ↑IGNITE program boosted Zinomax daily units by 22% YoY
  • ↓Negative earnings yield and poor profitability restrict cash flow generation
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for managing pain and chemotherapy-induced nausea. The company's portfolio includes the acute care product Zinomax (Zinrelief) and oncology products such as Sinvanti. Positioned at the intersection of acute care and oncology, Heron aims to leverage its established products and execute strategic partnerships while navigating a competitive healthcare landscape.

Bull says

  • ↑Q1 net revenue $34.7M, up 32% YoY with March sales over $15M
  • ↑IGNITE program boosted Zinomax daily units by 22% YoY
  • ↑2026 net product sales guidance of $173–183M with $10–20M adjusted EBITDA
  • ↑Permanent J-Code approvals streamline reimbursement and widen access
  • ↑Rebound in elective surgeries expected to drive pain‐management demand
  • ↑Adequate liquidity supports obligations and underpins growth recovery

Bear says

  • ↓Negative earnings yield and poor profitability restrict cash flow generation
  • ↓Elevated leverage and stock volatility heighten financial instability
  • ↓Analyst revisions trending downward, casting doubt on growth outlook
  • ↓Nasdaq minimum bid-price warning underscores valuation pressure
  • ↓Patent litigation over Cinvanti poses long-term revenue threat
  • ↓Small company size limits scale advantages against larger peers

Investment themes with HRTX

Biotech↑ +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR
High Dividend Yield↑ +0.15%

Companies paying above-average dividends

AISP · SMR · NWL

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-11-2026neutral

Transcript signals

Bull points

  • We have seen consistent and accelerating adoption across our device preparation platforms as we transition from the vented vial spike, or VVS, to the significantly improved vial access needle, or VAN.
  • the ZENERLEFT PFS is fully funded and on track.
  • It was designed to align with contemporary health system expectations, including both ASHP and Joint Commission guidance, while improving operating room workflow, reducing preparation steps, and lowering the risk of medication errors and contamination.

Bear points

  • the first quarter of any year historically brings seasonal headwinds driven by copay resets and insurance adjustments, and this year was no exception.
  • Two weeks of severe weather early in the quarter that significantly compounded the typical seasonal softness, making January our most difficult month since I joined the company.
  • The impact of the weather was felt most acutely in elective surgeries, which are highly sensitive to extreme conditions and saw a sharp decline during that period.
Read full transcript analysis ›